Quick Answer
Taysha Gene Therapies, Inc. reported Operating Income Loss of -$110.50 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed a decrease of -20.8% in Operating Income Loss from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$31.0 thousand | Q4 2019: -$1.12 million | Q1 2020: -$5.58 million | Q2 2020: -$4.01 million | Q3 2020: -$15.04 million | Q1 2021: -$32.09 million | Q2 2021: -$40.77 million | Q3 2021: -$50.68 million | Q1 2022: -$49.65 million | Q2 2022: -$33.37 million | Q3 2022: -$25.46 million | Q1 2023: -$16.56 million | Q2 2023: -$23.38 million | Q3 2023: -$16.25 million | Q1 2024: -$24.33 million | Q2 2024: -$21.30 million | Q3 2024: -$25.90 million | Q1 2025: -$21.42 million | Q2 2025: -$26.75 million | Q3 2025: -$34.02 million.
- Over the full 6 years of available data (2020 to 2025), Taysha Gene Therapies, Inc.'s Operating Income Loss has declined by 157.0%.
- Historical annual values: Fiscal year 2025: -$110.50 million | Fiscal year 2024: -$91.46 million | Fiscal year 2023: -$72.44 million | Fiscal year 2022: -$162.45 million | Fiscal year 2021: -$173.27 million | Fiscal year 2020: -$43.00 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: